Are overweight and obesity risk factors for invasive mechanical ventilation in severe coronavirus disease 2019 pneumonia?

Maria Fernanda Coss-Rovirosa
https://orcid.org/0000-0003-3739-3453

Mercedes Aguilar-Soto
https://orcid.org/0000-0002-3622-8406

Dalia Cuenca
https://orcid.org/0000-0001-9961-4667

Mariana Velez-Pintado
https://orcid.org/0000-0002-7834-4917

Antonio Camiro-Zuñiga
https://orcid.org/0000-0003-0957-0569

Aldo Ferreira-Hermosillo
https://orcid.org/0000-0002-5159-9866

Moises Mercado
https://orcid.org/0000-0002-4748-9734

ABSTRACT

Objective: Describe the demographic, clinical, and biochemical characteristics of overweight or obese people with severe COVID-19 pneumonia and evaluate its association with mechanical ventilation requirements in a Mexican cohort. Subjects and methods: Data were obtained from medical electronic records. Patients were divided in three groups according to the World Health Organization (WHO) classification of body mass index (BMI): lean, overweight and obese. Baseline characteristics and clinical course were compared among these 3 groups. Results: The study included a total of 355 patients with confirmed COVID-19 diagnoses. Patients with obesity and overweight, according to the WHO classification, had no significantly increased risk of requiring intubation and invasive mechanical ventilation (IMV) compared to lean subjects, with an odds ratio (OR) of 1.82 (95% CI, 0.94-3.53). A post hoc and multivariate analysis using a BMI > 35 kg/m² to define obesity revealed that subjects above this cut off had as significantly increased risk of requiring IMV after with an OR of 2.86 (95% CI, 1.09-7.05). Conclusions: We found no higher risk of requiring IMV in patients with overweight or obesity while using conventional BMI cutoffs. According to our sensitivity analyses, the risk of IMV increases in patients with a BMI over 35 kg/m².

Keywords
Overweight; obesity; COVID-19; invasive mechanical ventilation (IMV)

INTRODUCTION

In December 2019, the new coronavirus SARS-CoV-2 was described for the first time in China’s Wuhan province (1). In under 4 months, the virus caused the greatest pandemic of the century.

By September 27, 2020, the World Health Organization (WHO) had reported nearly 33,000,000 cases and over 900,000 deaths worldwide most of them on the American continent. Mexico has reported 817,000 cases since its first case in February 2020 and a mortality rate of 11%, higher than the worldwide average (2).

An age over 65 years and the presence of comorbidities are the main risk factors for hospitalization (3). Diabetes, hypertension, and obesity comprise the most common preexisting conditions (4). Obesity, defined as a body mass index (BMI) of > 30 kg/m², commonly appears in COVID-19 patients, with a 47% prevalence in patients requiring hospitalization (5). Previous studies demonstrate that patients with obesity have a high risk for a severe disease. These patients often require invasive mechanical ventilation (IMV) and have a higher mortality rate than non-obese patients.

Copyright © AE&M all rights reserved.
In fact, a one-unit increase in BMI likely increases the risk of severe disease by 12% (6). One cohort study showed that obesity (BMI ≥ 30 kg/m²) is a strong, independent, and clinically relevant risk factor for severe illness leading to intubation or death (7).

In Mexico, obesity’s prevalence has risen substantially in the last 30 years and now affects over 35% of the adult population (8). Obesity associates with other conditions, including cardiovascular disease, type 2 diabetes mellitus, cancer, obstructive sleep apnea, and more (9). Aside from these metabolic complications, patients with obesity have a chronic inflammatory state (10), mediated by the adipose tissue’s secretion of proinflammatory cytokines, such as adiponectin, interleukin-6 (IL-6), interleukin-1, and tumor necrosis factor-α. Thus, patients with obesity have an altered innate immune response that negatively affects COVID-19 outcomes (11).

We describe the demographic, clinical, and biochemical characteristics of patients with obesity and overweight and evaluate the association with an IMV requirement.

**SUBJECTS AND METHODS**

**Study design and setting**

From March 12 to July 15 of 2020, we collected information from patients admitted to the American British Cowdray Medical Center, a private teaching hospital in Mexico City. Clinical, biochemical, and imaging information was obtained and analyzed retrospectively. We included patients 18 years old or older who had a documented diagnosis of COVID-19 (defined as a positive PCR for SARS-CoV2 or a chest CT scan showing characteristics of COVID-19 pneumonia). Data came from the hospital’s electronic medical records. We included all patients with height, weight, and outcome data; we excluded patients with missing values. The scientific and ethics committees of the medical center approved the protocol, and the study followed the principles of the Helsinki declaration.

**Study procedures**

As stated before, a COVID-19 diagnosis was defined as a positive PCR for SARS-CoV2 or a chest CT scan showing characteristics of COVID-19. We obtained samples for SARS-CoV-2 testing according to the Centers for Disease Control guidelines. Nucleic acid was extracted with the RNeasy Mini Kit (Qiagen), and we used a 7500 Real-Time PCR System (Applied Biosystems) targeting the CoV E gene and the CoV RdRP gene for nucleic acid amplification. Positive chest CT scans occurred when characteristics of COVID-19 were verified by a consensus among several radiologists.

Patients were classified according to the WHO classification of overweight and obesity. A normal BMI is between 18.5 and 24.9 kg/m², an overweight BMI ranges from 25-29.9 kg/m², and obesity BMI is > 30 kg/m². The main outcome was mechanical ventilation requirement at admission or during hospitalization, as recorded in electronic medical records. We also evaluated days of hospital stay as a secondary outcome.

**Statistical analysis**

Depending on data distribution (via the Shapiro Wilks test), continuous variables are described as means with standard deviations (normally distributed) or as a median interquartile range (abnormally distributed). We used frequencies and simple proportions to summarize categorical variables. We used ANOVA to compare groups with normal BMI patients, patients with overweight, and patients with obesity. We conducted univariate, age- and sex-adjusted, and multivariate logistic regressions to evaluate the need for IMV in normal, overweight, and patients with obesity. We also adjusted for possible confounders, such as C-reactive protein levels, oxygen-saturation levels, and mean arterial pressure on admission. We conducted a linear regression analysis using continuous BMI to assess the days of a hospital stay. The same covariates were used for the logistic regression analysis.

Few patients had a normal BMI, so we conducted a sensitivity analysis defining the reference group as patients with a normal or overweight BMI. We also conducted a sensitivity analysis, defining obesity as a BMI over 35 kg/m². All statistical tests were 2-sided, and a p-value < 0.05 was considered statistically significant. We used SAS University Edition version 9.4 statistical software (SAS Institute, Cary, NC).

**RESULTS**

This study included a total of 355 patients with confirmed COVID-19 diagnoses. Table 1 depicts the baseline characteristics of patients, who were divided in three groups according to their BMI. Of the patients, 23% (n = 82) had normal BMI, 45% (n = 160) were
Table 1. Baseline characteristics of patients divided by BMI classification

| Categories of weight | Normal (n=82) | Overweight (n=160) | Obesity (n=113) | p value |
|----------------------|--------------|--------------------|----------------|---------|
| BMI                  | 23.4 (22.2-24.4) | 27.4 (26.1-28.4) | 33.7 (31.6-36.4) | <0.0001 |
| Age, years           | 56.8 (17.3)   | 53.3 (15.7)       | 50.8 (13.2)     | <0.0001 |
| Women n, (%)         | 33 (40)       | 54 (34)           | 33 (29)         | 0.28    |
| Prediabetes n, (%)   | 1 (2)         | 9 (7)             | 5 (5)           | 0.27    |
| Diabetes n, (%)      | 15 (19)       | 25 (16)           | 21 (19)         | 0.83    |
| Hypertension n, (%)  | 21 (26)       | 42 (27)           | 36 (32)         | 0.53    |
| Severity Scales      |              |                   |                |         |
| NEWS (11)            | 5 (4-7)       | 6 (4-7)           | 6 (5-8)         | 0.11    |
| MULBSTA (12)         | 7 (5-10)      | 9 (5-11)          | 7 (5-11)        | 0.67    |
| CALL-SCORE (13)      | 7 (5-10)      | 7 (6-10)          | 7 (6-10)        | 0.79    |
| Laboratory values    |              |                   |                |         |
| Leucocytes (10^3/μL) | 6 (5-9)       | 7 (5-10)          | 6 (5-8)         | 0.03    |
| Neutrophils (10^3/μL)| 5 (3.1-7.5)   | 5.9 (3.7-8.3)     | 5 (3-7)         | 0.18    |
| Lymphocytes (10^3/μL)| 1.0 (0.76-1.37)| 0.99 (0.66-1.46) | 1.02 (0.80-1.4)| 0.75    |
| Neutrophil/Lymphocyte Ratio | 4.8 (2.7-8) | 5.6 (3-9.4) | 4.8 (2.8-7.7) | 0.35 |
| Glucose (mg/dL)      | 115 (99-131.8)| 116 (98.4-134.9) | 114 (97-132)   | 0.77    |
| HDL-c (mg/dL)        | 33.5 (19-40)  | 35 (28-42)        | 31 (27-39)     | 0.256   |
| DL-c (mg/dL)         | 58.5 (31-79)  | 66.5 (47.5-83)    | 69 (52-93)     | 0.03    |
| Triglycerides (mg/dL)| 156 (80-156)  | 126 (95-176)      | 130 (100-183)  | 0.018   |
| CRP (mg/dL)          | 10.5 (4-17.5) | 12 (6-22)         | 11 (4-20)      | 0.27    |
| Ferritin (ng/mL)     | 762 (337-1385)| 897 (435-1623)    | 1075 (665-1602)| 0.11    |
| IL-6 (pg/mL)         | 25.5 (16.5-54.5)| 38 (16-67)     | 39 (15-63)    | 0.57    |
| D-dimer (ng/mL)      | 1000 (760-2320)| 790 (529-1219) | 796 (505-1256)| 0.11    |
| Treatment            |              |                   |                |         |
| Lopinavir/Ritonavir n, (%) | 39 (49) | 109 (68)       | 68 (61)        | 0.01    |
| Azithromycin n, (%)  | 58 (72)       | 117 (74)          | 92 (82)        | 0.17    |
| Hidroxicloroquine n, (%) | 63 (72) | 126 (80)       | 92 (81)        | 0.31    |
| Glucocorticoids n, (%) | 6 (7)    | 13 (8)           | 5 (4)          | 0.35    |
| Tocilizumab n, (%)   | 21 (27)       | 66 (44)           | 48 (46)        | 0.02    |
| Outcomes             |              |                   |                |         |
| Required ICU n, (%)  | 9 (13)        | 24 (16)           | 24 (22)        | 0.15    |
| Admitted to ICU n, (%) | 31 (38)   | 56 (35)          | 37 (33)        | 0.26    |
| Required mechanical ventilation n, (%) | 22 (27) | 56 (35) | 43 (38) | 0.25 |
| Death (%)            | 7 (9)         | 13 (8)            | 4 (4)          | 0.25    |

1 Values are percentages, mean ± SD or median (IQR) as appropriate. HDL-c = High density lipoprotein, LDL = Low density lipoprotein, CRP = C-reactive protein, IL-6 = Interleukin 6.

overweight, and 32% (n = 113) were patients with obesity. The median BMI for each group was 23.4 (22.2-24.4) kg/m², 27.4 (26.1-28.4) kg/m², and 33.7 (31.6-36.4) kg/m², respectively. The mean age was significantly lower (p < 0.0001) in patients with obesity (50.8 ± 13.2 years) compared to those with a normal BMI (56.8 ± 17.5 years). The normal BMI group had a higher proportion of women (40%), with lower percentages of women for overweight (34%) or obesity (29%).

The prevalence of prediabetes (2% of normal BMI patients, 7% of overweight patients, and 5% of patients with obesity, p=0.27), diabetes (normal BMI = 19%, overweight = 16%, obese = 19%, p = 0.83) and...
hypertension (normal BMI = 26%, overweight = 27%, obese = 32%, p = 0.53) was similar among all groups. Other important comorbidities had a prevalence of 2% for chronic kidney disease, 2.4% for heart disease, and 2% for chronic obstructive pulmonary disease without significant differences among groups (p = 0.38, 0.6, and 0.37, respectively). Cancer’s prevalence differed significantly, with 9% in lean patients, 1% in patients with overweight and 4% in patients with obesity (p = 0.015). No between-group difference in severity existed according to validated scores, such as the National Early Warning Score (12) (p = 0.11), MuLBSTA (13) (p = 0.67), and CALL (14) (p = 0.79) scores. Laboratory data were obtained on admission for all values for all patients. The normal BMI and patients with obesity groups had lower leucocyte counts compared to the overweight group (p = 0.03). The groups had similar levels of other inflammatory markers (lymphocyte count, D Dimer, C reactive protein, ferritin, and interleukin-6).

The 3 groups had similar HDL-cholesterol levels, but patients with obesity had higher LDL-c levels. Patients with normal BMI had higher triglyceride levels compared to those who were overweight or obese. All patients were treated with supplemental oxygen by regular nasal cannula or mask upon admission to the hospital. Oxygen was administered via high-flow nasal cannula to 17% of lean individuals, 48% of patients with overweight and 36% of patients with obesity (p = 0.30). Continuous positive airway pressure was used for 5 patients with overweight and 5 patients with obesity. The revised version of the manuscript specifies those details. Secondary infections did not differ between the 3 groups. Bacterial pneumonia was diagnosed in 8% of the patients, without a difference among groups (p = 1). Invasive pulmonary aspergillosis had an overall incidence of 4.2% and was similar between groups (p = 0.33). No significant differences exist in ICU admission, the need for mechanical ventilation, or mortality rate (6% in the general group). The median number of days from symptom onset to hospitalization was 8.5 (6-12, p = 0.33).

Compared to patients with normal BMI, patients with overweight and obesity were more likely to require IMV, but the risk only remained significant for patients with obesity when adjusting for age and sex (OR 1.82, 95% CI, 1.02-3.79). The risk was no longer significant in the multivariate analysis (OR 1.82, 95% CI, 0.94-3.53; Table 2).

When conducting sensitivity analyses with normal BMI and patients with overweight together as reference, patients with obesity had a higher risk of requiring IMV and an increased OR after multivariable adjustment (OR 2.04, 95% CI, 1.09-3.81). Considering obesity as having a BMI > 35 kg/m², analyses showed an increased risk of requiring IMV after a multivariate adjustment with an OR of 2.86 (95% CI, 1.09-7.05; Table 3).

Increased BMI associated with a longer hospital stay according to a bivariate analysis (OR of 1.44), but a multivariate analysis adjusting for age and sex made this association lose statistical significance (OR 1.19). The number of days of a hospital stay positively correlated with the days before a negative PCR after the first positive PCR (r = 0.60, p value < 0.0001).

### Table 2. Risk for requiring mechanical ventilation among patients with overweight or obesity

|          | Normal (n=89) | Overweight (n=160) | Obesity (n=114) |
|----------|--------------|--------------------|-----------------|
| Reference| 1.47 (0.82-2.6) | 1.7 (0.90-3.1)    |                 |
| Reference| 1.63 (0.88-3.01) | 1.97 (1.02-3.79)  |                 |
| Reference| 0.67 (0.29-1.53) | 1.82 (0.94-3.53)  |                 |

1 Values are Odds Ratio (95% CI) unless otherwise specified.
2 Model is multivariate analysis adjusted for age (continuous), sex (men or women), mean arterial pressure on admission (continuous), C reactive protein levels on admission (continuous), oxygen saturation on admission (continuous, percentage).

### Table 3. Risk for requiring mechanical ventilation considering obesity as BMI >35 kg/m²

|          | Without obesity (n=318) | Obesity (n=37) |
|----------|------------------------|---------------|
| Reference| 1.55 (0.77-3.08)       | 2.06 (0.99-4.28) |
| Reference| 2.86 (1.09-7.5)        |               |

1 Values are Odds Ratio (95% CI) unless otherwise specified.
2 Model is multivariate analysis adjusted for age (continuous), sex (men or women), mean arterial pressure on admission (continuous), C reactive protein levels on admission (continuous), oxygen saturation on admission (continuous, percentage).

### DISCUSSION

Obesity and COVID-19 coexist as pandemics in 2020, and obesity associates with increases in the severity, the need for mechanical ventilation, and mortality among these patients (15). In this study, we analyzed a cohort of 355 COVID-19 patients in Mexico City to compare the clinical characteristics and outcomes of lean, patients with overweight and obesity.

The prevalence of patients with overweight and obesity in our study was 31% and 45%, respectively, and
only 24% of patients had a normal BMI. A different cohort of COVID-19 patients in Mexico reported the prevalence of patients with overweight and obesity as 34.9% and 35.9%, respectively (16). The prevalence of patients with obesity and overweight in Mexico’s general population, according to recent data, is 36.1% and 39.1%, respectively, which aligns with data in our cohort (7).

We divided our cohort into 3 groups according to WHO definitions: normal, overweight, and obesity (BMI > 30 kg/m²). We found no significant association between patients with overweight or with obesity and a higher risk of requiring IMV. However, when conducting sensitivity analyses defining obesity as having a BMI > 35 kg/m², we found a higher risk of IMV (OR 2.86, 95% CI, 1.09-7.5). Overall, patients in the 3 groups received most treatments with similar frequencies. However, tocilizumab and lopinavir/ritonavir were more frequently prescribed for patients with overweight and obesity. The decision to initiate each treatment was based on the criteria of the attending physician, but none of these treatments impacted final outcomes (17,18).

Similar findings showed obesity as a risk factor for developing severe COVID-19, with the greatest impact in patients with a BMI ≥ 35 kg/m². In addition, 90% of this group of patients needed IMV (5). In a similar study in California, a BMI cutoff of > 40 kg/m² showed a greater risk of death after adjusting for obesity-related comorbidities (RR = 2.68, 95% CI, 1.43-5.04) (19).

These findings support that class II obesity (according to the WHO classification) constitutes a risk factor for needing IMV, but not for patients with overweight or those with class I obesity (20). Obesity-related comorbidities that might act as confounders (such as diabetes and hypertension) were similar in the three groups and did not associate with IMV in univariate analyses.

Patients with obesity have lower mortality in some chronic diseases. Similarly, patients with obesity have a lower acute respiratory distress syndrome associated mortality than does the general population (21). This phenomenon – the obesity paradox for chronic diseases – might also affect patients with COVID-19. Nevertheless, this paradox may merely reflect a selection bias (22). Early reports on COVID-19 suggested patients with overweight and with obesity had an increased risk of complications, so it may be prudent to hospitalize these patients even if they present with mild disease (23). Another explanation for why overweight subjects and patients with lower grades of obesity have no higher risk for IMV is the concept of metabolically healthy obese patients. These patients have a preserved insulin sensitivity, a lower liver fat content, lower visceral fat mass, and normal adipose tissue function, conferring them a lower risk of mortality in some chronic diseases. This is further supported because obesity-related comorbidities, such as diabetes and hypertension, were similar in the three groups, as were glucose levels on admission but not for triglycerides and LDL-c levels (24).

For patients with class II or higher obesity, several mechanisms might increase their risk of mechanical ventilation. Adipose tissue is a proinflammatory tissue with an increased expression of cytokines, particularly adipokines like leptin, which associate with an increased inflammatory response, reduced ciliary clearance, and acute respiratory distress syndrome. A delayed immune response that impairs the response to infectious agents also appears in patients with obesity (21).

On the other hand, patients with obesity have excess body weight and poor pulmonary reserve, which alters pulmonary gas exchange and respiratory mechanics. This could necessitate early intubation and IMV due to an extremely rapid O2 desaturation, particularly in patients with higher degrees of obesity (25).

Our results show obesity could constitute an important risk factor for severe diseases requiring IMV, but only in patients with a BMI > 35 kg/m². Other studies found similar results but did not compare categories of patients of overweight or obesity using the conventional BMI cutoff > 30 kg/m². These findings suggest that only higher degrees of obesity increase the risk for IMV and worse outcomes with COVID-19. Not all patients with obesity and overweight might have the same risk, so they should be carefully evaluated to avoid preventive hospitalization when presenting a mild disease.

This study has some limitations, including its retrospective nature and its lack of non-hospitalized patients. However, it represents a tertiary care center’s experience, which can support prospective studies around the country.

We conclude that patients with obesity, defined by the WHO as having a BMI > 30 kg/m², hospitalized for a SARS-CoV-2 infection had a similar risk for IMV compared to lean patients. The increased risk for IMV only appeared in patients with class II obesity.
Acknowledgments: the members of the Asociación de Residentes de Medicina Interna en Investigación (ARMII) arc: Mercedes Aguilar-Soto MD, Marivna Covadonga Ansoleaga-García MD, Guillermo Bracamontes-Castelo MD, Arturo Cadena-Fernández MD, Antonio Camiro-Zúñiga MD, Tábata Cano-Gámez MD, María Fernanda Coss-Rovirosa MD, Laura Crespo-Ortega MD, Dalía Cuenca MD, Adolfo Díaz Cabral MD, J. Antonio García-Gordillo MD, Victor Hugo Gomez-Johnson MD, Giza González-Calderón MD, Juan Pablo Guillermo-Durán, MD, Isabel Gutiérrez-Lozano MD, Stefany Jacob Kuttathora MD, Rodolfo Jiménez-Soto MD, AlejandraKerbel Laiter MD, José Carlos Krause Martín MD, Ana Paula Landeta-Sa MD, Víctor José Leal Alcántara MD, María Luisa Montes de Oca-Loyola MD, Santiago Montiel-Romero MD, Cecilia Nehmad Misri MD, Renzo Pérez-Dórame MD, Alma Nelly Rodríguez-Alcocer MD, Carlos Andrés Rodríguez-Toledo MD, Andrea Romo López MD, Marína Rotzinger-Rodriguez MD, Jorge Carlos Salado-Burbano MD, Latife Salame Khouri MD, Rodrigo Sánchez Magallán MD, Isaac Octavio Vargas-Olmos MD, Walter Valé-Uitzil MD, and Marína Vélez-Pintado MD.

Disclosure: no potential conflict of interest relevant to this article was reported.

REFERENCES

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33.
2. WHO. Situation Report. Coronavirus Disease (COVID-19). 2020. Consulted: October 13th, 2020.
3. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020 May 22;369:m1966.
4. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW; the Northwell COVID-19 Research Consortium, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052-9.
5. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noutette J, Duhamel A, et al. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation. Obesity. 2020;28(7):1195-9.
6. Tartof SY, Qian L, Hong V, Wei R, Nadjafe RF, Fischer H, et al. Obesity and Mortality Among Patients Diagnosed With COVID-19: Results From an Integrated Health Care Organization. Ann Intern Med. 2020;173(10):773-81.
7. Frank RC, Mendez SR, Stevenson EK, Guseh JS, Chung M, Silverman MG. Obesity and the Risk of Intubation or Death in Patients With Coronavirus Disease 2019. Crit Care Med. 2020;48(11):e1097-e1101.
8. Instituto Nacional de Salud Pública. Encuesta Nacional de Salud y Nutrición. Ensanut. 2018;47.
9. DiBonaventura MD, Meinkke H, Le Lay A, Fournier J, Bakker E, Ehrenreich A. Obesity in Mexico: prevalence, comorbidities, associations with patient outcomes, and treatment experiences. Diabetes Metab Syndr Obes. 2017;11:1-10.
10. Sattar N, McInnes IB, McMurray JJV. Obesity Is a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms. Circulation. 2020;142(11):4-6.
11. Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, Vargas-Vázquez A, González-Díaz A, Márquez-Salinas A, et al. Predicting Mortality Due to SARS-CoV-2: A Mechanistic Score Relating Obesity and Diabetes to COVID-19 Outcomes in Mexico. J Clin Endocrinol Metabol. 2020;105(8):diaa346.
12. Jang JG, Hur J, Hong KS, Lee W, Ahn JH. Prognostic Accuracy of the SIRS, qSOFA, and NEWS for Early Detection of Clinical Deterioration in SARS-CoV-2 Infected Patients. J Korean Med Sci. 2020;35(25):e234.
13. Guo L, Wei D, Zhang X, Wu Y, Li Q, Zhou M, Qu J. Clinical Features Predicting Mortality Risk in Patients With Viral Pneumonia: The MulBSTA Score. Front Microbiol. 2019;10:2752.
14. Ji D, Zhang D, Xu J, Chen Z, Yang T, Zhao P, et al. Prediction for Progression Risk in Patients With COVID-19 Pneumonia: The CALL Score. Clin Infect Dis. 2020;71(6):1393-9.
15. Caussy C, Wallet F, Laville M, Disse E. Obesity is Associated with Severe Forms of COVID-19. Obesity. 2020;28(7):1175.
16. Ortiz-Brizuela E, Villanueva-Reze M, González-Lara MF, Tamez-Torres KM, Román-Montes CM, Diaz-Mejia BA, et al. Clinical and epidemiological characteristics of patients diagnosed with COVID-19 in a tertiary care center in Mexico City: A prospective cohort study. Rev Invest Clin. 2020;72(3):165-77.
17. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020 May 7;382(19):1787-99.
18. Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, et al.; RCT-TCZ-COVID-19 Study Group. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2021;181(11):24-31.
19. Tartof SY, Qian L, Hong V, Wei R, Nadjafe RF, Fischer H, Li Z, Shaw SF, Caparosa SL, Nau CL, Saxena T, Rieg GK, Ackerson BK, Sharp AL, Skarbinski J, Naïk TK, Murali SB. Obesity and Mortality Among Patients Diagnosed With COVID-19: Results From an Integrated Health Care Organization. Ann Intern Med. 2020;173(10):773-81.
20. James PT, Leach R, Kalamaras E, Shayeushi M. The worldwide obesity epidemic. Obes Res. 2001;9 Suppl 4:2285-233S.
21. Ni YN, Luo J, Yu H, Wang YW, Hu YH, Liu D, et al. Can body mass index predict clinical outcomes for patients with acute lung injury/acute respiratory distress syndrome? A meta-analysis. Crit Care. 2017;21(11):36.
22. Lajous M, Banack HR, Kaufman JS, Hernán MA. Should patients with chronic disease be told to gain weight? The obesity paradox and selection bias. Am J Med. 2015;128(4):334-6.
23. van der Voort PHJ, Moser J, Zandstra DF, Muller Kobold AC, Knoester M, Calkhoven CF, et al. Leptin levels in SARS-CoV-2 infection related respiratory failure: A cross-sectional study and a pathophysiological framework on the role of fat tissue. Heliyon. 2020;6(8):e04696.
24. Bluhm M. Are metabolically obese individuals are really healthy? Eur J Endocrinol. 2014;171(6):R209-19.
25. Lemzye M, Courageux N, Maladobry T, Arumadura C, Paquet P, Orfi A, et al. Implications of Obesity for the Management of Severe Coronavirus Disease 2019 Pneumonia. Crit Care Med. 2020;48(9):e761-7.